Fritextsökning
Innehållstyper
-
ZEISS Quality Innovation Days: April 15 – 19, 2024
Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma
Webinar | March 13, 2024, 12 PM EST.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Level up your medical expertise
Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.
-
The First Multi-Technology System from ZEISS
Microscope and measuring machine in one.
-
Positive trend for Swedish medtech exports – “We have new markets that are huge”
In 2024, Swedish exports of pharmaceuticals decreased for the first time in several years. However, the trend for medical technology looks brighter. During a se...
-
Don't miss ZEISS Quality Innovation Days
Digital event April 15-19, 2024.
-
The Crucial Role of Core Imaging Facility Managers
User story from ZEISS and the University of York.
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
Precision and accuracy in liquid handling
How to evaluate and optimize liquid handling performance
-
Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy
Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 1...
-
Sustainability at Festo
On the Way to the Net Zero Era - New Sustainability Report published
-
Automated dispensing of liquids
Have a look at how you can do easier and faster dispensing on the fly adapted to your needs
-
ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin
More than 50 distinguished speakers from leading manufacturing companies.
-
ZEISS Lightfield 4D for instant volumetric high-speed imaging
Capturing physiological and neuronal processes in 3D.
-
First preterm infants study – a vital step for Neola
After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on p...
-
“I am driven by the desire to develop a product that can be sold worldwide”
Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...